Abstract
Material and methods. We recruited 64 women with migraine (episodic and chronic) over 18 years of age with regular menstrual cycle. 21 patients were diagnosed with MRM according to the International Classification of Headache Disorders, 3rd edition. Demographic data, migraine history, menstrual cycle characteristics and algodysmenorrhea symptoms were collected. Patients were treated with erenumab or fremanezumab for 3 months and followed up monthly with headache diaries.
Results. After 3 months of treatment, the intensity of menstrual migraine attacks and algodysmenorrhea decreased by 50% or more (p=0,03* and p=0,045*, accordingly). There was a significant decrease in the total amount of headache days in MRM patients.
Conclusion. Anti-CGRP mAbs are effective in MRM and algodysmenorrhea. Further studies are necessary.
Key words: migraine, monoclonal antibodies, Erenumab, Fremanezumab, CGRP, menstrual-related migraine, algodysmenorrhea.
For citation:Berdnikova A.V., Kadymova N.B., Latysheva N.V., Naprienko M.V., Filatova E.G. Anti-CGRP monoclonal antibodies in the treatment of migraine in women: impact on menstrual relared migraine and algodysmenorrhea. Clinical review for general practice. 2023; 4 (10): 90–94 (In Russ.). DOI: 10.47407/kr2023.4.10.00347
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.